1. WILEX AG
1.1 Business Overview
1.2 WILEX AG Cancer Pipeline Overview

2. WILEX AG Cancer Drugs in Research Phase
2.1 Antibody-Drug Conjugates - Advanced Proteome Therapeutics/ Heidelberg Pharma

3. WILEX AG Cancer Drugs in Preclinical Phase
3.1 Antibody Targeted Amanitin Conjugates - Heidelberg Pharma
3.2 Antibody Therapeutics - F-star
3.3 PSMA ATAC Therapeutics - Heidelberg Pharma
3.4 Antibody-Drug Conjugates – Heidelberg

4. WILEX AG Cancer Drugs in Clinical Phase
4.1 Girentuximab Companion Diagnostic - Wilex/Nuclea Biotechnologies

5. WILEX AG Cancer Drugs in Phase-II/III
5.1 Girentuximab-Zr-89

6. Discontinued in Cancer Drugs in Clinical Pipeline
6.1 Imexon - Heidelberg Pharma
6.2 Cancer Therapeutics – Heidelberg
6.3 Anthracyclines - Galilaeus Oy
6.4 HDP 990007

7. Suspended in Cancer Drugs in Clinical Pipeline
7.1 Girentuximab
7.2 Fosfluridine Tidoxil
7.3 Clofarabine - Heidelberg Pharma


List of Figures

Figure 1-1: WILEX AG Cancer Pipeline by Phase (%)
Figure 1-2: WILEX AG Cancer Pipeline by Phase (Number)
Figure 1-3: WILEX AG Cancer Pipeline by Phase (%)
Figure 1-4: WILEX AG Cancer Pipeline by Phase (Number)